tiprankstipranks
Trending News
More News >
Nippon Chemiphar Co., Ltd. (JP:4539)
:4539
Japanese Market

Nippon Chemiphar Co., Ltd. (4539) Price & Analysis

Compare
1 Followers

4539 Stock Chart & Stats


Financials

4539 FAQ

What was Nippon Chemiphar Co., Ltd.’s price range in the past 12 months?
Nippon Chemiphar Co., Ltd. lowest stock price was ¥1410.00 and its highest was ¥1675.00 in the past 12 months.
    What is Nippon Chemiphar Co., Ltd.’s market cap?
    Nippon Chemiphar Co., Ltd.’s market cap is ¥5.34B.
      When is Nippon Chemiphar Co., Ltd.’s upcoming earnings report date?
      Nippon Chemiphar Co., Ltd.’s upcoming earnings report date is Jul 30, 2025 which is in 50 days.
        How were Nippon Chemiphar Co., Ltd.’s earnings last quarter?
        Nippon Chemiphar Co., Ltd. released its earnings results on May 14, 2025. The company reported ¥71.9 earnings per share for the quarter, beating the consensus estimate of N/A by ¥71.9.
          Is Nippon Chemiphar Co., Ltd. overvalued?
          According to Wall Street analysts Nippon Chemiphar Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Nippon Chemiphar Co., Ltd. pay dividends?
            Nippon Chemiphar Co., Ltd. pays a Annually dividend of ¥50 which represents an annual dividend yield of 3.38%. See more information on Nippon Chemiphar Co., Ltd. dividends here
              What is Nippon Chemiphar Co., Ltd.’s EPS estimate?
              Nippon Chemiphar Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Nippon Chemiphar Co., Ltd. have?
              Nippon Chemiphar Co., Ltd. has 4,261,420 shares outstanding.
                What happened to Nippon Chemiphar Co., Ltd.’s price movement after its last earnings report?
                Nippon Chemiphar Co., Ltd. reported an EPS of ¥71.9 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.923%.
                  Which hedge fund is a major shareholder of Nippon Chemiphar Co., Ltd.?
                  Currently, no hedge funds are holding shares in JP:4539

                  Company Description

                  Nippon Chemiphar Co., Ltd.

                  Nippon Chemiphar Co., Ltd., together with its subsidiaries, manufactures, markets, imports, exports, and sells, ethical pharmaceuticals and diagnostic agents in Japan and internationally. It offers diagnostic products, such as IgE NC, a diagnostic kit that provides results and reveals total IgE levels, as well as 57 individual allergen reagents; and DP3000, a device for allergen-specific IgE measurements. The company also develops NC-2400, a PPAR-delta agonist; NC-2500, a novel advanced xanthine oxidoreductase inhibitor for the treatment of hyperuricemia/gout; and NC-2600, a P2X4 receptor antagonist for the treatment of neuropathic pain. In addition, it develops NC-2700, a novel urate transporter 1 inhibitor that enhance excretion urate to urine; NC-2800, a delta opioid receptor agonist for the treatment of depression/anxiety; Uralyt-U, an alkalization therapeutic drug; Soleton, an analgesic and anti-inflammatory drug; and Calvan, a hypertension therapeutic drug. Further, the company provides quasi-drugs, nutrients, health foods, cosmetics, and various type of creams. It distributes its generic pharmaceuticals through wholesalers to hospitals and pharmacies. The company was formerly known as Hitachi Chemical Co., Ltd. and changed its name to Nippon Chemiphar Co., Ltd. in 1970. Nippon Chemiphar Co., Ltd. was founded in 1950 and is headquartered in Tokyo, Japan.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Wakamoto Pharmaceutical Co., Ltd.
                  Morishita Jintan Co., Ltd.
                  Fuso Pharmaceutical Industries,Ltd.
                  KYORIN Pharmaceutical Co.,Ltd.
                  Symbio Pharmaceuticals Limited
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis